| http://purl.uniprot.org/citations/18820258 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/18820258 | http://www.w3.org/2000/01/rdf-schema#comment | "Two novel mutations (G159D and L29Q) in cardiac troponin C (CTnC) associate their phenotypic outcomes with dilated (DCM) and hypertrophic cardiomyopathy (HCM), respectively. Current paradigms propose that sarcomeric mutations associated with DCM decrease the myofilament Ca2+ sensitivity, whereas those associated with HCM increase it. Therefore, we incorporated the mutant CTnCs into skinned cardiac muscle in order to determine if their effects on the Ca2+ sensitivities of tension and ATPase activity coincide with the current paradigms and phenotypic outcomes. The G159D-CTnC decreases the Ca2+ sensitivity of tension and ATPase activation and reduces the maximal ATPase activity when incorporated into regulated actomyosin filaments. Under the same conditions, the L29Q-CTnC has no effect. Surprisingly, changes in the apparent G159D-CTnC Ca2+ affinity measured by tension in fibers do not occur in the isolated CTnC, and large changes measured in the isolated L29Q-CTnC do not manifest in the fiber. These counterintuitive findings are justified through a transition in Ca2+ affinity occurring at the level of cardiac troponin and higher, implying that the true effects of these mutations become apparent as the hierarchical level of the myofilament increases. Therefore, the contractile apparatus, representing a large cooperative machine, can provide the potential for a change (G159D) or no change (L29Q) in the Ca2+ regulation of contraction. In accordance with the clinical outcomes and current paradigms, the desensitization of myofilaments from G159D-CTnC is expected to weaken the contractile force of the myocardium, whereas the lack of myofilament changes from L29Q-CTnC may preserve diastolic and systolic function."xsd:string |
| http://purl.uniprot.org/citations/18820258 | http://purl.org/dc/terms/identifier | "doi:10.1074/jbc.m804070200"xsd:string |
| http://purl.uniprot.org/citations/18820258 | http://purl.uniprot.org/core/author | "Potter J.D."xsd:string |
| http://purl.uniprot.org/citations/18820258 | http://purl.uniprot.org/core/author | "Dweck D."xsd:string |
| http://purl.uniprot.org/citations/18820258 | http://purl.uniprot.org/core/author | "Hus N."xsd:string |
| http://purl.uniprot.org/citations/18820258 | http://purl.uniprot.org/core/date | "2008"xsd:gYear |
| http://purl.uniprot.org/citations/18820258 | http://purl.uniprot.org/core/name | "J Biol Chem"xsd:string |
| http://purl.uniprot.org/citations/18820258 | http://purl.uniprot.org/core/pages | "33119-33128"xsd:string |
| http://purl.uniprot.org/citations/18820258 | http://purl.uniprot.org/core/title | "Challenging current paradigms related to cardiomyopathies. Are changes in the Ca2+ sensitivity of myofilaments containing cardiac troponin C mutations (G159D and L29Q) good predictors of the phenotypic outcomes?"xsd:string |
| http://purl.uniprot.org/citations/18820258 | http://purl.uniprot.org/core/volume | "283"xsd:string |
| http://purl.uniprot.org/citations/18820258 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/18820258 |
| http://purl.uniprot.org/citations/18820258 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/18820258 |
| http://purl.uniprot.org/uniprot/#_P63316-mappedCitation-18820258 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/18820258 |
| http://purl.uniprot.org/uniprot/#_Q6FH91-mappedCitation-18820258 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/18820258 |
| http://purl.uniprot.org/uniprot/P63316 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/18820258 |
| http://purl.uniprot.org/uniprot/Q6FH91 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/18820258 |